Data came from the UK Rheumatoid Arthritis Medication Study (RAMS), a prospective cohort of early RA patients starting methotrexate (MTX) shows that in the first year, adverse events (AE) were common, but not serious.
A total of 1069 patients were enrolled and followed at 6 and 12 month intervals. Adverse events were noted:
The July 2021 RheumNow “Live Vote” surveyed US and non-US rheumatologists on their knowledge and practices when dealing with the bone disorder, X-linked hypophosphatemia (XLH). Although rare, XLH can be a diagnostic consideration in patients with recurrent fractures, rickets, osteomalacia and a family history of fractures.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout.
Two recent analyses from the USA and Canada point to a significant unmet need with regard to pediatric rheumatologists.
The 2015 pediatric rheumatology workforce in the US was evaluated by the American College of Rheumatology, estimating the Pediatric rheumatology supply and demand projected through 2030.
The 2022 ACR/EULAR revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA) have been revised and validated for use in clinical research.
This international cohort of vasculitis and comparator cases were to develop and validate criteria based on 91 candidate variables. By regression analysis these were narrowed to 11 items for the diagnosis of EPGA; 7 of which were retained.
The ACR/EULAR 2022 revised classification criteria for granulomatosis with polyangiitis (GPA) have been updated with performance characteristics and are validated for use in clinical research.
The 2022 ACR/EULAR classification criteria for microscopic polyangiitis (MPA) have been developed, validated and are now ready for use in clinical research.
An international cohort of patients with vasculitis or comparator diseases were recruited to first develop criteria and then validate criteria.
A prospective cohort from the Nurses’ Health Study has demonstrated that eating a healthy diet results in a 12% to 32% lower risk of incident gout and an even greater risk reduction (65% to 68%) when combined with normal weight and avoiding diuretics.
The ACR has updated its clinical guidance for the use of COVID-19 vaccination in patients with musculoskeletal disorders (MSK).
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week a trifecta of Gout reports and the last word on the ORAL Surveillance study...
In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.
For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.
A randomized trial compared the incremental cost-effectiveness of physical therapy and intra-articular glucocorticoid (IA GC) injection as initial treatment for knee osteoarthritis showed that physical therapy gained more quality-adjusted life-years compared with those receiving glucocorticoid injection.
A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.
There is guidance published on how to manage moderate to severe cases, but very few blueprints detail what to do with “mild” infection. The first day, I developed congestion and cough, with a sore throat. As the day progressed, I started to have chills, low grade fevers, and myalgias. The postnasal drainage was overwhelming, and when I tried to swallow, it felt like swallowing broken glass.
Isolating in my room, I was
